Zimbabwe Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Zimbabwe Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Zimbabwe Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Zimbabwe's health sector will deteriorate over the short term as a result of significant cuts to national budget allocations. Despite the distribution to healthcare growing over the last seven years, it remains far from meeting the global commitment agreed in Abuja in 2001 of 15% of the national budget. Government revenue earning capabilities have declined as Zimbabwe's main exports are suffering from lower commodity prices, as well as diminishing taxable income from stagnant economi c growth. This will negatively affect Zimbabwe's healthcare delivery over the short term. Over the long term, continued reliance on foreign aid will discourage investment from drugmakers.

Headline Expenditure Projections

Pharmaceuticals: USD380mn in 2015 to USD399mn in 2016; +5.0% in US dollar terms. Forecast unchanged from last quarter .

Headline Pharmaceuticals & Healthcare Forecasts (Zimbabwe 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 0.361 0.380 0.399 0.418 0.437 0.456 0.475
Pharmaceutical sales, % of GDP 2.60 2.79 2.89 2.93 2.89 2.79 2.64

Risk/Reward Index

In BMI's Risk/Reward Index (RRI) for Q2 2016, Zimbabwe scores a poor 25.0 out of 100, down from last quarter's score of 25.3. The country is the least attractive out of the 31 markets surveyed in the Middle East and Africa region, just below Nigeria (26.0) and Angola (27.3). Zimbabwe will remain one of the least-attractive pharmaceutical and healthcare markets regionally and globally, due to the elevated political, economic and social risks, as well as the lack of finances for adequate healthcare provision and capacity utilisation.

Latest Updates

  • In February 2016, the Zimbabwean health minister along with health ministers and representatives from 19 other African countries signed a declaration promoting the use of vaccines to protect people of all ages against vaccine-preventable diseases, and to close the immunisation gap by 2020.

  • Zimbabwe's 2016 budget will see just USD330mn allocated to the healthcare sector, corresponding to merely 9.7% of the USD4bn national budget and significantly smaller than the Abuja target of 15%.

  • In February 2016, the Zimbabwean government began its first ever HIV vaccine trial as part of a global effort to curb the spread of the disease in the country.

  • The Zimbabwean government has revived its interest in universal healthcare by announcing plans to implement a new national health insurance scheme for the majority of the population.

BMI Economic View

Economic growth in Zimbabwe will barely creep above zero in 2016 as the effects of drought; low commodity prices and weak levels of foreign investment keep the economy in the doldrums.

BMI Political View

Political instability in Zimbabwe will increase in the next two years, ahead of the 2018 general election. The ruling ZANU-PF party looks set to retain dominance, though succession questions will intensify as ailing president Robert Mugabe's rule approaches its end.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Zimbabwe 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Zimbabwe 2012-2020)
13
Healthcare Market Forecast
14
Prescription Drug Market Forecast
16
Patented Drug Market Forecast
17
Generic Drug Market Forecast
18
Pharmaceutical Trade Forecast
19
Table: Pharmaceutical Trade Data And Forecasts (Zimbabwe 2014-2020)
21
Industry Risk/Reward Index
22
Middle East and Africa Risk/Reward Index - Q2 2016
22
Zimbabwe Risk/Reward Index
29
Rewards
29
Risks
29
Regulatory Review
31
Regulatory Regime
31
Intellectual Property Issues
33
Pricing And Reimbursement Regime
34
Market Overview
37
Healthcare Sector
38
Table: Zimbabwe: Healthcare Facilities
38
Healthcare Funding
40
Research & Development
44
Clinical Trials
45
Epidemiology
45
Competitive Landscape
48
Table: Multinational Market Activity
51
Pharmaceutical Retail Sector
51
Company Profile
53
Datlabs
53
Varichem Laboratories
55
Demographic Forecast
58
Table: Population Headline Indicators (Zimbabwe 1990-2025)
59
Table: Key Population Ratios (Zimbabwe 1990-2025)
59
Table: Urban/Rural Population & Life Expectancy (Zimbabwe 1990-2025)
60
Table: Population By Age Group (Zimbabwe 1990-2025)
60
Table: Population By Age Group % (Zimbabwe 1990-2025)
61
Glossary
63
Methodology
65
Pharmaceutical Expenditure Forecast Model
65
Healthcare Expenditure Forecast Model
65
Notes On Methodology
66
Risk/Reward Index Methodology
67
Index Overview
68
Table: Pharmaceutical Risk/Reward Index Indicators
68
Indicator Weightings
69

The Zimbabwe Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Zimbabwe Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Zimbabwe pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Zimbabwe, to test other views - a key input for successful budgeting and strategic business planning in the Zimbabwean pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Zimbabwean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Zimbabwe.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.